



				am Chopra 1D (Pathology) ant Pathologist	
NAME	: Mr. CHANDER MOHAN				
AGE/ GENDER	: 50 YRS/MALE	PATIENT ID		: 1675830	
COLLECTED BY	:	R	EG. NO./LAB NO.	: 012411190009	
REFERRED BY	:	REGISTRATION DATE		: 19/Nov/2024 08:30 AM	
BARCODE NO.	:01521061	COLLECTION DATE		: 19/Nov/2024 08:34AM	
CLIENT CODE. CLIENT ADDRESS	: KOS DIAGNOSTIC LAB : 6349/1, NICHOLSON ROAD,		EPORTING DATE	: 19/Nov/2024 10:34AM	
Test Name		Value	Unit	Biological Reference interval	
	CLINIC	CAL CHEMIST	RY/BIOCHEMIST	RY	
		LIPID PROF			
CHOLESTEROL TO by CHOLESTEROL O		188.23	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0	
TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)		138.48	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0	
HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION		40.95	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 60.0 HIGH HDL: > OR = 60.0	
LDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY		119.58	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0	
NON HDL CHOLES' by Calculated, spe		147.28 ^H	mg/dL	VERY HIGH: > OR = 190.0 OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0	
VLDL CHOLESTER		27.7	mg/dL	VERY HIGH: > OR = 220.0 0.00 - 45.00	
by CALCULATED, SPE TOTAL LIPIDS: SEF	RUM	514.94	mg/dL	350.00 - 700.00	
by CALCULATED, SPE CHOLESTEROL/HI by CALCULATED, SPE		4.6 ^H	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0	

KOS Diagnostic Lab (A Unit of KOS Healthcare)

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: Ilnd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.





MD (Pathology	/ & Microbiology)		(Pathology)		
: Mr. CHANDER MOHAN					
: 50 YRS/MALE		PATIENT ID	: 1675830		
:		REG. NO./LAB NO.	: 012411190009		
:		REGISTRATION DATE	: 19/Nov/2024 08:30 AM		
:01521061		COLLECTION DATE	: 19/Nov/2024 08:34AM		
: KOS DIAGNOSTIC LAB		REPORTING DATE	: 19/Nov/2024 10:34AM		
: 6349/1, NICHOLSON ROAD, AMBALA CANTT					
	Value	Unit	Biological Reference interval		
CTROPHOTOMETRY	2.92 3.38	RATIO RATIO	MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0 3.00 - 5.00		
	MD (Patholog) Chairman & C : Mr. CHANDER MOHAN : 50 YRS/MALE : : : : 01521061 : KOS DIAGNOSTIC LAB	: Mr. CHANDER MOHAN : 50 YRS/MALE : : : 01521061 : KOS DIAGNOSTIC LAB : 6349/1, NICHOLSON ROAD, AMBALA CANTT Value ERUM :CTROPHOTOMETRY 2.92	MD (Pathology & Microbiology) Chairman & Consultant Pathologist MD CEO & Consultant : Mr. CHANDER MOHAN : 50 YRS/MALE PATIENT ID : REG. NO./LAB NO. : REGISTRATION DATE : 01521061 COLLECTION DATE : KOS DIAGNOSTIC LAB REPORTING DATE : 6349/1, NICHOLSON ROAD, AMBALA CANTT Value Unit		

INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

End Of Report ***





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com

